EP Patent

EP3300729A1 — Therapeutic compositions containing macitentan

Assigned to Actelion Pharmaceuticals Ltd · Expires 2018-04-04 · 8y expired

What this patent protects

The invention relates to macitentan or a pharmaceutically acceptable salt thereof, for use in the treatment of pulmonary hypertension, wherein macitentan is to be administered in combination with a compound having prostacyclin receptor (IP) agonist properties which is 2-{4-[(5,6-…

USPTO Abstract

The invention relates to macitentan or a pharmaceutically acceptable salt thereof, for use in the treatment of pulmonary hypertension, wherein macitentan is to be administered in combination with a compound having prostacyclin receptor (IP) agonist properties which is 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}- N -(methylsulfonyl) acetamide, or a pharmaceutically acceptable salt thereof. It also relates to 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}- N -(methylsulfonyl)acetamide, or a pharmaceutically acceptable salt thereof, for use in the treatment of pulmonary hypertension, wherein 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}- N -(methylsulfonyl)acetamide is to be administered in combination with macitentan, or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP3300729A1
Jurisdiction
EP
Classification
—
Expires
2018-04-04
Drug substance claim
No
Drug product claim
No
Assignee
Actelion Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.